Schrödinger takes a step for­ward with Al­phaFold in drug R&D, as biotech hits a pipeline 'in­flec­tion'

Schrödinger has work­shopped a fix for one of the biggest prob­lems with Al­phaFold-gen­er­at­ed pro­tein struc­ture pre­dic­tions, in what the com­pa­ny is de­scrib­ing as a no­table im­prove­ment on an AI tech­nol­o­gy that’s used across bio­phar­ma.

Al­phaFold is one of the most high-pro­file ex­am­ples of AI’s im­pact on bi­ol­o­gy, and can gen­er­ate pre­dic­tions of the shape of a pro­tein based on its amino acid se­quence. But be­cause those pre­dic­tions aren’t per­fect, it has lim­it­ed Al­phaFold’s use­ful­ness in drug dis­cov­ery — it’s been de­scribed as a “valu­able hy­poth­e­sis” gen­er­a­tor, but with warn­ings that it can’t re­place ex­per­i­men­tal da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER